LONDON, Oct. 14, 2021 /PRNewswire/ — In a significant milestone for its (AI)-driven drug discovery platform, BenevolentAI has nominated a preclinical candidate for a novel ulcerative colitis target, and plans to advance the asset into clinical trials. Scientists deployed BenevolentAI’s…